Post-earnings recap
Reported
Wed, Feb 25, 2026
EPS actual
$-1.22
EPS est.
$-1.00
EPS surprise
-22.37%
1-day move
+24.07%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Despite missing on EPS expectations, Celldex Therapeutics saw a significant stock increase of 24.07%. This positive market reaction may be attributed to investor optimism regarding the company's future strategies and potential developments. The lack of revenue data and guidance suggests uncertainty, but the stock's rise indicates confidence in management's long-term vision.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.22 | N/A | -22.37% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns over current market conditions but highlighted their commitment to long-term strategies. They did not provide specific guidance for future quarters.
Management acknowledged the challenges faced this quarter.
They emphasized ongoing efforts to enhance operational efficiency.